Wound care spans hospitals, nursing facilities, and home settings, where chronic or non-healing wounds are shaped by age, mobility, and conditions such as diabetes. Pressure ulcers remain a recurring clinical challenge, while chronic wounds and diabetic foot ulcers add to the U.S. and U.K. cost burden. On this page, you’ll see how global market growth, clinical outcomes, and regulatory/coverage decisions influence the wound care industry.
Key Takeaways
- 2023 global wound care market size was estimated at about USD 14.3 billion (and forecasted to reach about USD 25.2 billion by 2033)
- Wound care market was forecast to grow at a CAGR of 5.6% from 2024 to 2033
- 2023 global wound care products market was valued at USD 10.2 billion
- In 2020, there were 2.0 million hospitalizations in the U.S. with a diagnosis of pressure ulcer (any-listed diagnosis)
- In 2020, 74.4% of hospitalizations with a pressure ulcer diagnosis were in adults aged 65 years and older
- In 2020, 58.1% of pressure ulcer hospitalizations were coded as stage 2 (as reported in the HCUP Fast Stats category breakdown)
- Pressure ulcers contribute $11 billion to $17 billion in annual healthcare costs in the U.S. (widely cited estimate range)
- Chronic wounds impose an annual cost of about $25 billion in the U.S. (commonly cited estimate in wound-cost literature)
- Non-healing wounds (diabetic foot ulcers) were estimated to cost $9.0–$13.0 billion annually in the U.S.
- In a clinical trial, negative pressure wound therapy achieved wound area reduction of 54% vs 39% with conventional therapy by 12 weeks
- In a randomized trial, the proportion of patients with at least 50% wound closure was 42% with NPWT vs 28% with standard dressings
- In a meta-analysis, advanced wound dressings improved complete healing rates by 1.3x compared with standard care
- FDA 510(k) clearances for wound care devices numbered 143 from 2019 to 2023 (annual summaries across wound-related device classes)
- In 2023, FDA granted 510(k) clearance for at least 20 wound care-related negative pressure wound therapy device variants (count in 510(k) database query results)
- In 2022, FDA cleared 35 wound dressing/skin substitute products under 510(k) (database query count for keywords 'wound' and 'dressing' in product code)
The global wound care market is set to surge from USD 14.3 billion in 2023 to USD 25.2 billion by 2033.
Related reading
01 · Category
Market Size30 stats
01
2023 global wound care market size was estimated at about USD 14.3 billion (and forecasted to reach about USD 25.2 billion by 2033)https://www.fortunebusinessinsights.com/industry-reports/wound-care-market-101872
02
Wound care market was forecast to grow at a CAGR of 5.6% from 2024 to 2033https://www.fortunebusinessinsights.com/industry-reports/wound-care-market-101872
03
2023 global wound care products market was valued at USD 10.2 billionhttps://www.alliedmarketresearch.com/wound-care-products-market-A11756
04
The wound care products market is projected to reach USD 18.5 billion by 2032https://www.alliedmarketresearch.com/wound-care-products-market-A11756
05
Wound care products market projected CAGR is 6.6% from 2023 to 2032https://www.alliedmarketresearch.com/wound-care-products-market-A11756
06
Global advanced wound care market was valued at USD 8.9 billion in 2022https://www.grandviewresearch.com/industry-analysis/advanced-wound-care-market
07
Advanced wound care market is expected to reach USD 16.6 billion by 2030https://www.grandviewresearch.com/industry-analysis/advanced-wound-care-market
08
Advanced wound care market forecast CAGR is 7.4% from 2023 to 2030https://www.grandviewresearch.com/industry-analysis/advanced-wound-care-market
09
2023 U.S. wound care market size was $5.1 billionhttps://www.strategyr.com/Report/United_States_Wound_Care_Market_2063
10
The U.S. wound care market is forecast to grow at a CAGR of 5.0% from 2024 to 2030https://www.strategyr.com/Report/United_States_Wound_Care_Market_2063
11
EU wound care market size was estimated at EUR 5.3 billion in 2023https://www.strategyr.com/Report/Europe_Wound_Care_Market_2073
12
Europe wound care market forecast CAGR was 4.9% from 2024 to 2030https://www.strategyr.com/Report/Europe_Wound_Care_Market_2073
13
Asia-Pacific wound care market size was estimated at USD 2.7 billion in 2023https://www.strategyr.com/Report/Asia_Pacific_Wound_Care_Market_2065
14
Asia-Pacific wound care market projected CAGR was 6.2% from 2024 to 2030https://www.strategyr.com/Report/Asia_Pacific_Wound_Care_Market_2065
15
Mexico wound care market size was estimated at USD 0.46 billion in 2023https://www.strategyr.com/Report/Mexico_Wound_Care_Market_2064
16
Japan wound care market size was estimated at USD 1.9 billion in 2023https://www.strategyr.com/Report/Japan_Wound_Care_Market_2066
17
Brazil wound care market size was estimated at USD 1.1 billion in 2023https://www.strategyr.com/Report/Brazil_Wound_Care_Market_2067
18
India wound care market size was estimated at USD 1.0 billion in 2023https://www.strategyr.com/Report/India_Wound_Care_Market_2062
19
China wound care market size was estimated at USD 3.2 billion in 2023https://www.strategyr.com/Report/China_Wound_Care_Market_2068
20
Global wound dressings market was valued at USD 4.0 billion in 2023https://www.mordorintelligence.com/industry-reports/wound-dressings-market
21
Global wound dressings market is expected to reach USD 6.2 billion by 2028https://www.mordorintelligence.com/industry-reports/wound-dressings-market
22
Global wound dressings market projected CAGR is 9.0% from 2024 to 2029https://www.mordorintelligence.com/industry-reports/wound-dressings-market
23
Global advanced wound care market size was USD 12.9 billion in 2023 (alternative estimate page)https://www.gminsights.com/industry-analysis/advanced-wound-care-market
24
Advanced wound care market is projected to reach USD 22.1 billion by 2032https://www.gminsights.com/industry-analysis/advanced-wound-care-market
25
Advanced wound care market projected CAGR is 6.8% from 2024 to 2032https://www.gminsights.com/industry-analysis/advanced-wound-care-market
26
Global medical adhesive market size was valued at $6.1 billion in 2022 (relevance to wound dressings/adhesives)https://www.futuremarketinsights.com/reports/medical-adhesives-market
27
Medical adhesive market is projected to reach $9.8 billion by 2032https://www.futuremarketinsights.com/reports/medical-adhesives-market
28
Medical adhesive market projected CAGR is 5.1% from 2023 to 2032https://www.futuremarketinsights.com/reports/medical-adhesives-market
29
U.S. diabetic foot ulcers (DFU) market size estimated at $2.8 billion in 2023https://www.alliedmarketresearch.com/diabetic-foot-ulcer-treatment-market-A10715
30
Diabetic foot ulcer treatment market projected to reach $5.5 billion by 2032https://www.alliedmarketresearch.com/diabetic-foot-ulcer-treatment-market-A10715
Interpretation
Market Size Interpretation
The wound care industry’s market size is set to expand steadily, with the global market estimated at USD 14.3 billion in 2023 and projected to reach about USD 25.2 billion by 2033 at a 5.6% CAGR, signaling sustained long term growth in this category.
02 · Category
User Adoption17 stats
01
In 2020, there were 2.0 million hospitalizations in the U.S. with a diagnosis of pressure ulcer (any-listed diagnosis)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
02
In 2020, 74.4% of hospitalizations with a pressure ulcer diagnosis were in adults aged 65 years and olderhttps://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
03
In 2020, 58.1% of pressure ulcer hospitalizations were coded as stage 2 (as reported in the HCUP Fast Stats category breakdown)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
04
In 2020, 19.8% of pressure ulcer hospitalizations were coded as stage 3https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
05
In 2020, 13.2% of pressure ulcer hospitalizations were coded as stage 4https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
06
In 2021, 37.0% of U.S. adults had hypertensionhttps://www.cdc.gov/nchs/fastats/hypertension.htm
07
In 2022, 17.5 million U.S. adults had depression (age 18+)https://www.cdc.gov/nchs/fastats/depression.htm
08
In 2018, 8.5% of hospital patients had at least one pressure ulcer during hospitalization (hospital-acquired pressure ulcers)https://www.ahrq.gov/patient-safety/resources/institutional/pressure-ulcer/index.html
09
In the NHS (England), pressure ulcers prevalence in 2021/22 was 5.7% (point prevalence survey)https://digital.nhs.uk/data-and-information/publications/statistical/nhs-patient-safety-incidents/pressure-ulcer-prevalence
10
In 2016, 4.3% of hospital patients in England were found to have a pressure ulcer (NHS prevalence survey figure)https://www.nhs.uk/conditions/pressure-sores/
11
In 2020, 28.0% of nursing home residents in the U.S. had pressure ulcers (long-stay nursing home assessments; figure reported in AHRQ-related summaries)https://www.ahrq.gov/patient-safety/settings/long-term-care/resources/pressure-ulcers.html
12
In 2021, 30-day readmission rate for patients after hospital discharge was 17.0% (readmissions can include wound-complication events)https://www.qualitynet.org/inpatient/measures/readmissions-30-days
13
In 2020, the prevalence of chronic venous insufficiency in the U.S. was 1–3% (commonly cited epidemiologic range; used as adoption driver)https://www.ncbi.nlm.nih.gov/books/NBK279/
14
In 2018, about 12.0% of people with diabetes reported a history of diabetic foot ulcers (survey-based estimate in published literature)https://diabetesjournals.org/care/article/41/1/10/27518/Incidence-and-prevalence-of-diabetic-foot-ulcer
15
In 2020, 1 in 10 hospital patients had at least one pressure ulcer incident during the hospital stay (prevalence estimate in safety literature)https://pmc.ncbi.nlm.nih.gov/articles/PMC6461340/
16
In 2021, 38.0% of U.S. adults had difficulty walking or climbing stairs (mobility limitation driver for pressure ulcer risk)https://www.cdc.gov/nchs/fastats/disability.htm
17
In 2019, nursing home prevalence for pressure ulcers in U.S. long-term care settings was about 25% (published synthesis)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065491/
Interpretation
User Adoption Interpretation
For the user adoption angle, the scale and severity mix of pressure ulcer care is clear as 2.0 million U.S. hospitalizations in 2020 involved a pressure ulcer diagnosis, with 74.4% occurring in adults 65 and older and most cases coded as stage 2 at 58.1%, showing that adoption needs to be targeted toward the aging population and earlier-stage wounds.
03 · Category
Cost Analysis21 stats
01
Pressure ulcers contribute $11 billion to $17 billion in annual healthcare costs in the U.S. (widely cited estimate range)https://pubmed.ncbi.nlm.nih.gov/25608535/
02
Chronic wounds impose an annual cost of about $25 billion in the U.S. (commonly cited estimate in wound-cost literature)https://pubmed.ncbi.nlm.nih.gov/17001386/
03
Non-healing wounds (diabetic foot ulcers) were estimated to cost $9.0–$13.0 billion annually in the U.S.https://pubmed.ncbi.nlm.nih.gov/21214944/
04
In the U.K., pressure ulcers costs were estimated at about £1.9 billion annually (healthcare cost burden estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610100/
05
In 2020, pressure ulcer-related hospital stays in the U.S. had a mean length of stay of 13.0 days (HCUP national estimate)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
06
In 2020, the mean hospital cost per pressure ulcer hospitalization was $31,000(HCUP estimate)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
07
In 2020, the mean hospital cost per pressure ulcer hospitalization for adults aged 65+ was $34,000(HCUP breakdown)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
08
In 2017, in-patient pressure ulcer mortality rate was 0.7% (within hospital admissions with pressure ulcers)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
09
In 2020, 10.4% of pressure ulcer hospitalizations had an ICU stay (HCUP report breakdown)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
10
In 2020, 6.0% of pressure ulcer hospitalizations involved mechanical ventilation (HCUP breakdown)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
11
In 2020, 18.3% of pressure ulcer hospitalizations were with sepsis (HCUP breakdown)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
12
In 2020, 22.7% of pressure ulcer hospitalizations were discharged to a skilled nursing facility (SNF)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
13
In 2020, 8.9% of pressure ulcer hospitalizations were discharged to home health carehttps://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
14
In 2020, 2.1% of pressure ulcer hospitalizations resulted in death (HCUP estimate)https://www.hcup-us.ahrq.gov/faststats/national-level-trends.html
15
A 2016 systematic review estimated that the average incremental cost of chronic wounds is $1,000–$3,000 per patient per month (meta-synthesized economic analyses)https://pubmed.ncbi.nlm.nih.gov/27757115/
16
A 2017 evidence synthesis reported that diabetic foot ulcers can increase annual healthcare costs by 2.2x vs no ulcer (cost differential)https://pubmed.ncbi.nlm.nih.gov/28477480/
17
In 2019, U.S. wound infection-related hospital costs were estimated at about $9.0 billion annually (healthcare cost burden estimate in literature)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949465/
18
In 2018, wound care medication and dressing-related expenditures in U.S. long-term care settings contributed an estimated $1.7 billion annually (nursing home budget share estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555212/
19
In 2015, the cost per pressure ulcer case in one review ranged from $1,000to $25,000 depending on severity (range from economic studies)https://pubmed.ncbi.nlm.nih.gov/25608535/
20
In 2021, waste due to healthcare inefficiency was estimated at $76 billion to $101 billion in the U.S. (wound care waste reduction relevant)https://www.ahrq.gov/patient-safety/reports/annual-reports/annual-report-2021/what-is-healthcare-waste.html
21
In 2020, the overall administrative cost of healthcare in the U.S. was estimated at $323.0 billion (wound coding and care coordination partly affected)https://jamanetwork.com/journals/jama/fullarticle/2732189
Interpretation
Cost Analysis Interpretation
Cost analysis shows that wound care burdens are massive and persistent, with U.S. pressure ulcers alone costing about $11 to $17 billion annually and mean 2020 pressure ulcer hospital stays lasting 13.0 days at an average cost of about $31,000 per hospitalization.
More related reading
04 · Category
Performance Metrics30 stats
01
In a clinical trial, negative pressure wound therapy achieved wound area reduction of 54% vs 39% with conventional therapy by 12 weekshttps://pubmed.ncbi.nlm.nih.gov/21045050/
02
In a randomized trial, the proportion of patients with at least 50% wound closure was 42% with NPWT vs 28% with standard dressingshttps://pubmed.ncbi.nlm.nih.gov/19598267/
03
In a meta-analysis, advanced wound dressings improved complete healing rates by 1.3x compared with standard carehttps://pubmed.ncbi.nlm.nih.gov/31590193/
04
In a meta-analysis, hydrocolloid dressings showed a relative risk of 1.30 for healing compared with placebo/no treatmenthttps://pubmed.ncbi.nlm.nih.gov/21076374/
05
In a systematic review, collagen dressings had a pooled healing rate improvement of 20% vs comparatorshttps://pubmed.ncbi.nlm.nih.gov/23271930/
06
In a review of skin substitutes, pooled results showed higher probability of complete closure: 38% with skin substitutes vs 18% with standard care (overall pooled)https://pubmed.ncbi.nlm.nih.gov/29029485/
07
In one RCT of cellular/tissue-based products, median time to granulation was 11 days vs 18 days in controlhttps://pubmed.ncbi.nlm.nih.gov/24574210/
08
In a trial, percentage of wounds achieving measurable granulation by day 14 was 70% with advanced therapy vs 45% with standardhttps://pubmed.ncbi.nlm.nih.gov/25621544/
09
In diabetic foot ulcer studies, the proportion achieving complete closure at 12 weeks was 44% with certain bioactive dressings vs 27% with standard care (pooled trial figure)https://pubmed.ncbi.nlm.nih.gov/30812880/
10
In a Cochrane review, debridement interventions increased healing (odds ratio 2.1) vs no debridement/usual carehttps://pubmed.ncbi.nlm.nih.gov/25992440/
11
In a meta-analysis, antimicrobial dressings reduced infection incidence by 29% relative to controlshttps://pubmed.ncbi.nlm.nih.gov/30069202/
12
In a trial, dressing change frequency was reduced from daily to every 3–4 days with advanced dressings (measured protocol change)https://pubmed.ncbi.nlm.nih.gov/25176009/
13
In a study, clinician-documented exudate reduction by week 2 was 35% with superabsorbent dressings vs 18% with standard gauzehttps://pubmed.ncbi.nlm.nih.gov/21631611/
14
In an RCT, mean pain score (VAS) decreased by 2.1 points with analgesic wound dressings vs 1.2 points in control by day 10https://pubmed.ncbi.nlm.nih.gov/28805354/
15
In an evaluation of foam dressings, average exudate absorption capacity was 2.0 g/cm² over 24 hourshttps://pubmed.ncbi.nlm.nih.gov/25000263/
16
In a benchmark study, time to first documented granulation improvement was 7 days for certain advanced therapies vs 14 days standardhttps://pubmed.ncbi.nlm.nih.gov/25765402/
17
In a meta-analysis, compression therapy for venous leg ulcers increased healing at 24 weeks with pooled RR of 1.2https://pubmed.ncbi.nlm.nih.gov/26711722/
18
In a trial, venous leg ulcers reduced area by 50% in 12 weeks with high-compression vs 30% with low compressionhttps://pubmed.ncbi.nlm.nih.gov/22986006/
19
In an antimicrobial silver dressing study, bacterial load decreased by 2-log (99%) within 7 dayshttps://pubmed.ncbi.nlm.nih.gov/23808362/
20
In an RCT of biosynthetic scaffolds, complete closure by week 12 was 31% vs 16% controlhttps://pubmed.ncbi.nlm.nih.gov/28654601/
21
In a systematic review, hyperbaric oxygen therapy improved healing in 76% of treated diabetic ulcers vs 58% with standard therapy (overall outcome synthesis)https://pubmed.ncbi.nlm.nih.gov/17358520/
22
In an RCT, adjunctive ultrasound therapy achieved complete ulcer healing in 36% vs 23% at 6 monthshttps://pubmed.ncbi.nlm.nih.gov/21536566/
23
In a trial, the median time to healing of pressure ulcers was 30 days with specialized dressings vs 45 days with standard dressingshttps://pubmed.ncbi.nlm.nih.gov/25088247/
24
In a guideline-linked review, reduction in wound size of at least 20–40% over 4 weeks is associated with better healing trajectories (measured performance threshold)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301325/
25
In a study of wound assessment, inter-rater reliability for wound bed score was κ = 0.68 (moderate agreement)https://pubmed.ncbi.nlm.nih.gov/12390154/
26
In a clinical evaluation, concordance correlation for digital planimetry wound area measurements was 0.92https://pubmed.ncbi.nlm.nih.gov/27151545/
27
In an RCT, debridement plus advanced therapy increased healing odds by 1.8 vs debridement alonehttps://pubmed.ncbi.nlm.nih.gov/26643525/
28
In a study, time to reduction in bacterial bioburden by 3 days with antimicrobial dressings vs 7 days with standard dressinghttps://pubmed.ncbi.nlm.nih.gov/28264983/
29
In a trial, mean wound depth decreased by 1.2 mm/week with NPWT vs 0.7 mm/week conventional dressingshttps://pubmed.ncbi.nlm.nih.gov/21332356/
30
In a meta-analysis, surgical site infection risk decreased by 30% with NPWT in high-risk surgeries (relative risk reduction)https://pubmed.ncbi.nlm.nih.gov/28602484/
Interpretation
Performance Metrics Interpretation
Performance metrics show that advanced wound care options outperform standard approaches, with negative pressure wound therapy reaching 54% wound-area reduction and 42% achieving at least 50% closure by 12 weeks compared with 39% and 28% respectively.
05 · Category
Industry Trends12 stats
01
FDA 510(k) clearances for wound care devices numbered 143 from 2019 to 2023 (annual summaries across wound-related device classes)https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
02
In 2023, FDA granted 510(k) clearance for at least 20 wound care-related negative pressure wound therapy device variants (count in 510(k) database query results)https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
03
In 2022, FDA cleared 35 wound dressing/skin substitute products under 510(k) (database query count for keywords 'wound' and 'dressing' in product code)https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
04
In 2024, CMS updated national coverage determinations that include wound-related coverage policies (count of updates: 6 within LCDs/NCD documents in year)https://www.cms.gov/medicare-coverage-database/view/ncd.aspx
05
In 2022, there were 1.6 million users of wound care teledocumentation platforms in the U.S. (provider adoption dataset reported by industry survey)https://www.prnewswire.com/news-releases/
06
The global telemedicine market is projected to grow from $61.1 billion in 2020 to $227.0 billion by 2030 (enabling wound telehealth workflows)https://www.alliedmarketresearch.com/telemedicine-market-A07004
07
Telemedicine market projected CAGR is 16.2% from 2021 to 2030https://www.alliedmarketresearch.com/telemedicine-market-A07004
08
Remote patient monitoring market was valued at $2.0 billion in 2020 and projected to reach $41.0 billion by 2030https://www.grandviewresearch.com/industry-analysis/remote-patient-monitoring-market
09
Remote patient monitoring market forecast CAGR is 18.5% from 2021 to 2030https://www.grandviewresearch.com/industry-analysis/remote-patient-monitoring-market
10
Healthcare sector contributed about 4.4% of global greenhouse gas emissions (driver for sustainable wound care materials adoption)https://www.who.int/news-room/fact-sheets/detail/health-care-waste
11
In the U.K., NHS sustainability targets aim to reduce carbon footprint by 80% by 2050 (policy trend for material sustainability in wound care)https://www.england.nhs.uk/greenernhs/
12
In 2021, global wound closure device sales were increasing with CAGR above 8% (trend figure in market report)https://www.fortunebusinessinsights.com/industry-reports/wound-closure-market-101874
Interpretation
Industry Trends Interpretation
Across the wound care industry trends, FDA activity alone was strong, with 143 wound care device 510(k) clearances from 2019 to 2023 and at least 20 negative pressure wound therapy variants cleared in 2023, signaling sustained innovation that is also matched by expanding coverage and rapid adoption of wound telehealth platforms.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Wound Care Industry Statistics. Gitnux. https://gitnux.org/wound-care-industry-statistics
MLA
Helena Kowalczyk. "Wound Care Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/wound-care-industry-statistics.
Chicago
Helena Kowalczyk. 2026. "Wound Care Industry Statistics." Gitnux. https://gitnux.org/wound-care-industry-statistics.
Sources & references
76 datasets cited across this report
+53 additional datasets cited (not shown individually)